Legend Biotech(NASDAQ) LEGN

Market Cap$4.17B

Since IPO (2020)-42%

5 Year-45%

1 Year-39%

1 Month+13%

Premium Feature

Moneyball Superscore

71/100

$21.53

-1.03%

-0.22Today

After hours$21.53+$0.00 (+0.02%)

Legend Biotech last closing stock price
Metric	Price	Date
Last close	USD 21.52	2026-09-04

Legend Biotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+8.25%	USD 19.88	2026-08-28
1 month	+12.97%	USD 19.05	2026-08-05
3 month	-34.03%	USD 32.62	2026-06-05
Year to date	-1.01%	USD 21.74	2025-12-31
1 year	-38.5%	USD 34.99	2025-09-04
3 year	-68.7%	USD 68.75	2023-09-05
5 year	-44.74%	USD 38.94	2021-09-03
Since inception	-41.84%	USD 37.00	2020-06-05

Legend Biotech Financials at a Glance

Market Cap

$4.17B

Revenue (TTM)

$1.27B

Net Income (TTM)

-$91.60M

EPS (TTM)

-$0.51

P/E Ratio

-43.13

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$21.53

Volume

812,413.681

Open

$21.52

Price

$21.53

Volume

812,413.681

Open

$21.52

Previous Close

$21.52

Daily Range

$21.41 - $21.90

52-Week Range

$16.24 - $37.50

Estimated Earnings Date

Nov 11, 2026

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$21.53

Volume

812,413.681

Open

$21.52

Previous Close

$21.52

Daily Range

$21.41 - $21.90

52-Week Range

$16.24 - $37.50

Estimated Earnings Date

Nov 11, 2026

LEGN News

Page 1

LEGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Legend Biotech

Legend Biotech Corporation is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative cell therapies for oncology and other indications. The company operates primarily in the United States, China, and Europe, with its lead product candidate being ciltacabtagene autoleucel, a CAR-T therapy for multiple myeloma.

Products and Services

Lead product candidate: ciltacabtagene autoleucel (cilta-cel) for multiple myeloma
Portfolio of CAR-T therapies targeting various cancers, including acute lymphoblastic leukemia
Development of allogeneic CAR-T and CAR-NK product candidates for B-cell maturation antigen

Growth Outlook

Recent quarterly revenue of $387.5 million shows strong market demand
Collaboration with Janssen Biotech enhances development capabilities and market reach
Expansion into allogeneic therapies may diversify product offerings and revenue streams

Financial Highlights

Trailing twelve-month revenue of $1.3 billion indicates robust growth trajectory
Recent net income of $33.2 million reflects improved operational efficiency
Current ratio of 3.04 suggests strong liquidity position for future investments

Legend Biotech Corporation is positioned in the rapidly evolving biotechnology sector, focusing on advanced cell therapies. The company’s lead product, cilta-cel, is a promising treatment for multiple myeloma, and its ongoing collaborations with established pharmaceutical companies enhance its development and commercialization efforts. Recent financial performance indicates a positive trend, with significant revenue growth and a solid liquidity position, making it an intriguing option for investors interested in the biotechnology field.

AI Generated • Aug 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2,900

CEO

Ying Huang, PhD

Website

www.legendbiotech.com

Headquarters

Somerset, NJ 08873, US

LEGN Financials

Key Financial Metrics (TTM)

Gross Margin

56.58%

Operating Margin

-4.42%

Net Income Margin

-7.21%

Return on Equity

-8.70%

Return on Capital

-9.64%

Return on Assets

-5.23%

Earnings Yield

-2.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.17B

Shares Outstanding

193.77M

Volume

812.41K

Avg. Volume

2.41M

Financials (TTM)

Gross Profit

$719.24M

Operating Income

-$56.15M

EBITDA

-$7.24M

Operating Cash Flow

-$183.10M

Capital Expenditure

-$72.52M

Free Cash Flow

-$255.58M

Cash & ST Invst.

$964.63M

Total Debt

$278.21M

Legend Biotech Performance Analysis

Legend Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 116,865,974	69.6%
2023	2023-12-31	USD 284,895,135	143.8%
2024	2024-12-31	USD 627,555,610	120.3%
2025	2025-12-31	USD 1,031,621,169	64.4%

Legend Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	6.8%
Q4	2025-12-31	12.5%
Q1	2026-03-31	-0.4%
Q2	2026-06-30	27.0%

Legend Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -2.80	-2.3%
2023	2023-12-31	USD -2.94	4.9%
2024	2024-12-31	USD -0.97	-67.1%
2025	2025-12-31	USD -1.61	66.7%

Legend Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	67.6%
Q4	2025-12-31	22.7%
Q1	2026-03-31	-76.5%
Q2	2026-06-30	160.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$387.50M

+51.9%

Gross Profit

$250.10M

+59.2%

Gross Margin

64.54%

N/A

Market Cap

$4.17B

N/A

Market Cap/Employee

$1.30M

N/A

Employees

3,200

N/A

Net Income

$33.20M

+126.5%

EBITDA

$60.10M

+152.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$964.63M

-0.3%

Total Debt

$278.21M

-28.3%

Accounts Receivable

$198.01M

-13.5%

Inventory

$41.50M

+16.6%

Long Term Debt

$110.00M

-71.2%

Short Term Debt

$168.21M

+2748.0%

Return on Assets

-5.23%

N/A

Return on Invested Capital

-4.17%

N/A

Free Cash Flow

-$41.49M

-86.3%

Operating Cash Flow

-$20.90M

-60.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TARSTarsus Pharmaceuticals, Inc.

TARSTarsus Pharmaceuticals, Inc.$90.78+9.10%

ADPTAdaptive Biotechnologies Corporation

ADPTAdaptive Biotechnologies Corporation$24.28-1.18%

IDYAIDEAYA Biosciences, Inc.

IDYAIDEAYA Biosciences, Inc.$39.86-0.28%

CELCCelcuity Inc.

CELCCelcuity Inc.$95.70-0.76%

IRONDisc Medicine, Inc.

IRONDisc Medicine, Inc.$79.23-0.18%

ZLABZai Lab Limited

ZLABZai Lab Limited$26.23-2.85%

XENEXenon Pharmaceuticals Inc.

XENEXenon Pharmaceuticals Inc.$59.75-1.08%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.15-0.12%

NVDANvidia

NVDANvidia$230.36+0.01%

PATHUiPath

PATHUiPath$15.19-0.17%

INTCIntel

INTCIntel$95.80+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.13+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.74-0.02%

TSLATesla

TSLATesla$354.08-0.06%

Questions About LEGN

What is the current price of Legend Biotech?

Legend Biotech is trading at $21.52 per share.

What is the 52-week range for Legend Biotech?

Over the past 52 weeks, Legend Biotech has traded between $16.24 and $37.50.

How much debt does Legend Biotech have?

As of the most recent reporting period, Legend Biotech reported total debt of $278.21M.

How much cash does Legend Biotech have on hand?

Legend Biotech reported $672.92M in cash and cash equivalents in its most recent financial results.

What is Legend Biotech’s dividend yield?

Legend Biotech does not currently have a dividend yield.

Legend Biotech(NASDAQ) LEGN

Legend Biotech Financials at a Glance

LEGN News

2 Biotech Stocks Worth Buying Before Their Potential Buyouts

A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals

Why Legend Biotech Stock Crushed the Market on Monday

What Companies Does Johnson & Johnson Own?

After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech?

Why Shares of Legend Biotech Jumped Wednesday

Why Legend Biotech's Shares Jumped 14.2% On Tuesday

Why Legend Biotech's Shares Jumped 11.8% on Wednesday

LEGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Legend Biotech

LEGN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Legend Biotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About LEGN

What is the current price of Legend Biotech?

What is the 52-week range for Legend Biotech?

How much debt does Legend Biotech have?

How much cash does Legend Biotech have on hand?

What is Legend Biotech’s dividend yield?

Premium Investing Services